Topiramate use broadened

The licensed indications for topiramate (Topamax) in the UK have been broadened to ensure consistency with other European countries.

In epilepsy, Topamax monotherapy is now indicated for long-standing (as well as newly diagnosed) epilepsy and adjunctive therapy is no longer restricted to patients who are inadequately controlled on conventional first-line agents.

In migraine, treatment can now be initiated outside specialist care and no longer requires six-monthly review. In addition, prophylactic use of the drug can be considered regardless of the number and severity of migraines.

View Topamax drug record

Further information: Janssen-Cilag

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases